High mobility group box protein-1 correlates with microinflammatory state and nutritional status in continuous ambulatory peritoneal dialysis patients

Journal of Artificial Organs

Volumn 14, Issue 2, 2011, Pages 125-132

  Zhu, Nan ^a   Yuan, Weijie ^a   Zhou, Yi ^a   Liu, Jun ^a   Bao, Jinfang ^a   Hao, Jing ^a   Miao, Wen ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

HMGB 1; Inflammation; Malnutrition; Peritoneal dialysis

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CREATININE; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 6; PREALBUMIN; TUMOR NECROSIS FACTOR ALPHA; UREA;

ADULT; ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DIALYSATE LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MICROINFLAMMATION; NUTRITIONAL ASSESSMENT; NUTRITIONAL STATUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; SUBJECTIVE GLOBAL NUTRITIONAL ASSESSMENT; UREA BLOOD LEVEL; AGED; BLOOD; CHRONIC KIDNEY FAILURE; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; AGED; FEMALE; HMGB1 PROTEIN; HUMANS; INFLAMMATION; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NUTRITIONAL STATUS; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80055089878     PISSN: 14347229     EISSN: 16190904     Source Type: Journal    
DOI: 10.1007/s10047-011-0561-0     Document Type: Article

References (32)

1. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial. 2002;15:329-37.
2. Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome-the heart of the matter. Nephrol Dial Transplant. 2002;17:28-31. (Pubitemid 35277060)
3. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418:191-5. (Pubitemid 34773774)
4. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5:331-42. (Pubitemid 40516158)
5. Wang HL, Zhou CQ, Wang CL, Zhang L. Advancement in cytokine effect of high mobility group box 1 protein. Med Recapitul. 2009;15:963-6.
6. Urbonaviciute V, Fürnrohr BG, Weber C, Haslbeck M, Wilhilm S, Herrmann M, Voll RE. Factors masking HMGB1 in human serum and plasma. J Leukoc Biol. 2007;81:67-74. (Pubitemid 46021254)
7. Yanai H, Ban T, Wang ZC, Choi MK, Kawamura T, Negishi H, Nakasato M, Lu Y, Hangai S, Koshiba R, Savitsky D, Ronfani L, Akira S, Bianchi ME, Honda K, Tamura T, Kodama T, Taniguchi T. HMGB proteins function as universal sentinels for nucleicacid-mediated innate immune responses. Nature. 2009;462: 99-103.
8. Bruchfeld A, Qureshi AR, Lindholm B, Barany P, Yang LH, Stenvinkel P, Tracey KJ. High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med. 2008;14:109-15. (Pubitemid 351481841)
9. Yang H, Wang H, Czura CJ, Tracey KJ. The cytokine activity of HMGB1. J Leukoc Biol. 2005;78:1-8. (Pubitemid 40979937)
10. Pan HF, Wu GC, Li WP, Li XP, Ye DQ. High Mobility Group Box 1: a potential therapeutic target for systemic lupus erythematosus. Mol Biol Rep. 2010;37:1191-5.
11. Wanner C, Zimmermann J, Schwedler S, Metzger T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl. 2002;80:99-102.
12. Tsirpanlis G. The pattern of inflammation and a potential new clinical meaning and usefulness of C-reactive protein in endstage renal failure patients. Kidney Blood Press Res. 2005;28:55-61. (Pubitemid 40069637)
13. Zaza G, Pontrelli P, Pertosa G, Granata S, Rossini M, Porreca S, Staal FJT, Gesualdo L, Grandaliano G, Schena FP. Dialysisrelated systemic microinflammation is associated with specific genomic patterns. Nephrol Dial Transplant. 2008;23:1673-81. (Pubitemid 351767731)
14. Deppisch RM, Beck W, Goehl H, Ritz E. Complement components as uremic toxins and their potential role as mediators of microinflammation. Kidney Int Suppl. 2001;78:271-7.
15. Tsirpanlis G, Bagos P, Ioannou D, Bleta A, Marinou I, Lagouranis A, Chatzipanagiotou S, Nicolaou C. The variability and accurate assessment of the microinflammation in hemodialysis patients. Nephrol Dial Transplant. 2004;19:150-7. (Pubitemid 38072626)
16. Lazarus JM, Owen WF. Role of bioincompatibility in dialysis morbidity and mortality. Am J Kidney Dis. 1994;24:1019-32. (Pubitemid 24380477)
17. Kim SB, Kim SH, Lee MS, Chang JW, Lee SK, Park JS. Effects of sulodexide on hemostatic factors, lipid profile, and inflammation in chronic peritoneal dialysis patients. Perit Dial Int. 2007;27:456-60. (Pubitemid 47202199)
18. Klune JR, Dhupar R, Cardinal J, Billiar TR, Allan T. HMGB1: endogenous danger signaling. Mol Med. 2008;14:476-84.
19. Van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis. 2008;11:91-9.
20. Tsung A, Klune JR, Zhang X, Jeyabalan G, Cao ZX, Peng XM, Stolz DB, Geller DA, Rosengart MR, Billiar TR. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med. 2007;204:2913-23. (Pubitemid 350179560)
21. Fukami A, Adachi H, Yamagishi S, Matsui T, Ueda SI, Nakamura K, Enomoto M, Otsuka M, Kumagae SI, Nnajo Y, Kumagai E, Esaki E, Muratama K, Hirai Y, Imaizumi T. Factors associated with serum high mobility group box 1 (HMGB1) levels in a general population. Metabolism. 2009;58:1688-93.
22. Suda K, Takeuchi H, Ishizaka A, Kitagawa Y. High-mobilitygroup box chromosomal protein 1 as a new target for modulating stress response. Surg Today. 2010;40:592-601.
23. Panichi V, Maggiore U, Taccola D, Migliori M, Rizza GM, Consani C, Bertini A, Sposini S, Garcia RP, Rindi P, Palla R, Tetta C. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant. 2004;19:1154-60. (Pubitemid 38628135)
24. Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Filho RP, Stenvinkel P, Lindholm B. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis. 2006;47:139-48. (Pubitemid 41828276)
25. Prasad N, Gupta A, Sinha A, Singh A, Sharma RK, Kaul A. Impact of stratification of comorbidities on nutrition indices and survival in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int. 2009;29:153-7.
26. Christensson L, Unosson M, Ek AC. Evaluation of nutritional assessment techniques in elderly people newly admitted to municipal care. Eur J Clin Nutr. 2002;56:810-8.
27. Liu Y, Prasad R, Wilson SH. HMGB1: roles in base excision repair and related function. Biochim Biophys Acta. 2010;1799: 119-30.
28. Palumbo R, Sampaolesi M, Marchis DF, Tonlorenzi R, Colombetti S, Mondino A, Cossu G, Bianchi ME. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol. 2004;164:441-9. (Pubitemid 38174771)
29. Bilgic A, Akman B, Sezer S, Ozisik L, Arat Z, Ozdemir FN, Haberal M. Predictors for quality of life in continuous ambulatory peritoneal dialysis patients. Nephrology. 2008;13:587-92.
30. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Longterm effects of pravastatin on plasma concentrations of C-reactive protein. Circulation. 1999;100:230-5. (Pubitemid 29340127)
31. Tasic D. Evaluation of MIA syndrome in peritoneal dialysis patients. Med Pregl. 2007;60:170-2.
32. Ding HS, Yang J. High mobility group box-1 and cardiovascular diseases. Saudi Med J. 2010;31:48.